The National Institutes of Health (NIH) awarded a $28,924.80 firm fixed price purchase order contract to Cerus Corporation for the delivery of INTERCEPT Platelet Processing Sets with Dual Storage Containers. This sole-source contract is for the Department of Transfusion Medicine and will run from April 1, 2025 to September 30, 2025. Cerus Corporation's proprietary INTERCEPT technology is used to reduce the potential for virus replication in platelets, ensuring the safety of transfused blood products. This acquisition is being conducted under Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures, which allows for single-source procurement when only one source is reasonably available. There is no set-aside designation for this contract.
Generated 4/2/25, 10:07 AM